{"@context":{"obo_purl":"http://purl.obolibrary.org/obo/","rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","owl":"http://www.w3.org/2002/07/owl#","rdfs":"http://www.w3.org/2000/01/rdf-schema#","metadata_def":"http://data.bioontology.org/metadata/def/","metadata":"http://data.bioontology.org/metadata/","ns0":"http://purl.obolibrary.org/obo/chebi#"},"@graph":[{"@id":"obo_purl:CHEBI_70746","@type":"owl:Class","rdfs:subClassOf":[{"@id":"obo_purl:CHEBI_26421"},{"@id":"obo_purl:CHEBI_33308"},{"@id":"obo_purl:CHEBI_35359"},{"@id":"obo_purl:CHEBI_22715"},{"@id":"obo_purl:CHEBI_22823"},{"@id":"obo_purl:CHEBI_62733"}],"rdfs:label":"dabigatran etexilate","obo_purl:IAO_0000115":"An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of ethyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.","metadata:def/prefLabel":"dabigatran etexilate","metadata:def/mappingLoom":"dabigatranetexilate","metadata:def/mappingSameURI":{"@id":"obo_purl:CHEBI_70746"},"metadata:prefixIRI":"CHEBI:70746","obo_purl:RO_0000087":[{"@id":"obo_purl:CHEBI_50266"},{"@id":"obo_purl:CHEBI_50249"},{"@id":"obo_purl:CHEBI_65232"}],"ns0:is_conjugate_base_of":{"@id":"obo_purl:CHEBI_70751"},"ns0:has_functional_parent":{"@id":"obo_purl:CHEBI_70752"}},{"@id":"obo_purl:CHEBI_70751","ns0:is_conjugate_acid_of":{"@id":"obo_purl:CHEBI_70746"}}]}